ReviewJournal of molecular medicine (Berlin, Germany)2006
Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction.
Review in Journal of molecular medicine (Berlin, Germany), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 62 citations in OpenAlex.
- Elevated Levels of Serum Fibrin and Fibrinogen Degradation Products Are Independent Predictors of Larger Coronary Plaques and Greater Plaque Necrotic Core.Circulation journal : official journal of the Japanese Circulation Society · 2016Trial
- Earthworm fibrinolytic enzyme A and fibrin-derived peptide Bβ15-42 attenuate atherosclerosis via the VE-Cadherin signaling pathway.Atherosclerosis plus · 2025Article
- Activation of the Coagulation Cascade as a Universal Danger Sign.Current issues in molecular biology · 2025Review
- The potential value of fibrinogen-to-albumin ratio in assessing disease activity in rheumatoid arthritis.Frontiers in immunology · 2025Article
- The predictive value of serum fibrinogen and platelet distribution width for long-term cardiac death in acute myocardial infarction patients.Journal of thoracic disease · 2024Article
- Identification of Neural (N)-Cadherin as a Novel Endothelial Cell Receptor for Fibrin and Localization of the Complementary Binding Sites.Biochemistry · 2024Article
- Article
- Current View on the Molecular Mechanisms Underlying Fibrin(ogen)-Dependent Inflammation.Thrombosis and haemostasis · 2022Review
- Endotheliopathy is Associated with a 24-hour Fibrinolysis Phenotype Described by Low TEG Lysis and High D-Dimer after Trauma: a Secondary Analysis of the PROPPR Study.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2022Article
- Levels of Fibrin Degradation Products at Admission With Acute Ischemic Stroke Correlate With the NIH Stroke Scale Score 1 h After Intravenous Thrombolysis.Frontiers in neurology · 2021Article
- Focal adhesion kinase and Src mediate microvascular hyperpermeability caused by fibrinogen- γC- terminal fragments.PloS one · 2020Article
- Fibrin-VLDL Receptor-Dependent Pathway Promotes Leukocyte Transmigration by Inhibiting Src Kinase Fyn and is a Target for Fibrin β15-42 Peptide.Thrombosis and haemostasis · 2019Article
- Review
- Effect of fibrinogen, fibrin, and fibrin degradation products on transendothelial migration of leukocytes.Thrombosis research · 2018Article
- The Fibrin Cleavage Product BβFrontiers in pharmacology · 2018Article
- Article
- Endothelial fibrinolytic response onto an evolving matrix of fibrin.BMC hematology · 2016Article
- Interaction of Fibrin with the Very Low Density Lipoprotein Receptor: Further Characterization and Localization of the Fibrin-Binding Site.Biochemistry · 2015Article
- Immunobiology of fibrin-based engineered heart tissue.Stem cells translational medicine · 2015Article
- Tissue factor, protease activated receptors and pathologic heart remodelling.Thrombosis and haemostasis · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occlusion of a coronary artery leads to ischemia of the myocardium, while permanent occlusion results in cell death and myocardial dysfunction. Early restoration of blood flow is the only means to reduce or prevent myocardial necrosis, but-paradoxically-reperfusion itself contributes to injury of the heart. In animal models, this phenomenon is well described, and there are many different unrelated approaches to reduce reperfusion injury. In humans, however, pharmacological interventions have so far failed to reduce myocardial reperfusion injury. We summarize the pathogenesis of reperfusion injury, detailing the role of fibrin(ogen) and its derivatives. Moreover, we introduce a new concept for fibrin derivatives as potential targets for reperfusion therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.